REGENXBIO Inc - Company Profile
Powered by 
All the sales intelligence you need on REGENXBIO Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how REGENXBIO Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with REGENXBIO Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
REGENXBIO Inc (REGENXBIO) is a clinical-stage biotechnology company involved in the discovery and development of gene therapy. The company develops, commercializes, and licenses recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO's products include AAV plasmids, AAV vector reporter systems, and custom AAV vectors. The company’s gene therapy product candidates deliver genes to cells to address genetic defects and enable cells in the body to produce therapeutic proteins or antibodies that act on the disease. The company’s current pipeline products focus on therapy areas of retinal diseases, neuromuscular diseases and neurodegenerative diseases. Its NAV Technology Platform includes NAV Vectors to develop new AAV therapeutics. REGENXBIO is headquartered in Rockville, Maryland, the US.
Headquarters
United States of America
Address
9804 Medical Center Drive, Rockville, Maryland, 20850
Website
www.regenxbio.com
Telephone
1 240 5528181
No of Employees
371
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RGNX (NASD)
Revenue (2025)
$170.4M
104.5%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
14.6%
(2025 vs 2024)
Market Cap*
$676.7M
Net Profit Margin (2025)
XYZ
58.3%
(2025 vs 2024)
* As of and is in US$
REGENXBIO Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Regenexbio |
| RGX-111: Mucopolysaccharidosis Type I | NAV |
| RGX-121: Mucopolysaccharidosis Type II | Aaviate |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In March, the company entered into a partnership with Nippon Shinyaku to develop and commercialize RGX-121 for the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, and RGX-111 for Mucopolysaccharidosis I (MPS I), also known as Hurler syndrome. |
| 2023 | Contracts/Agreements | In May, the company announced that its NAV technology platform will support Bespoke Gene Therapy Consortium's first rare disease clinical portfolio. |
| 2022 | Others | In December, the company announced a comprehensive program update to outline its progress and development plans for RGX-181 and RGX-381. |
Competitor Comparison
| Key Parameters | REGENXBIO Inc | Eli Lilly and Co | Novartis AG | Sanofi | Regeneron Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | France | United States of America |
| City | Rockville | Indianapolis | Basel | Paris | Tarrytown |
| State/Province | Maryland | Indiana | Basel-Stadt | Ile-de-France | New York |
| No. of Employees | 371 | 50,605 | 75,267 | 76,493 | 15,410 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kenneth T. Mills | Chairman | Executive Board | 2024 | 51 |
| Curran M. Simpson | Chief Executive Officer; Director; President | Executive Board | 2024 | 64 |
| Mitchell Chan | Chief Financial Officer; Executive Vice President; Treasurer | Senior Management | 2024 | 45 |
| Craig Malzahn | Chief Technology Officer; Executive Vice President - Product Development | Senior Management | 2025 | 53 |
| Patrick J. Christmas II | Chief Legal Officer | Senior Management | - | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer